Cargando…

The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis

BACKGROUND: Biopsy is the usual gold standard for liver steatosis assessment. The aim of this study was to identify a panel of biomarkers (SteatoTest), with sufficient predictive values, for the non-invasive diagnosis of steatosis in patients with or without chronic liver disease. Biomarkers and pan...

Descripción completa

Detalles Bibliográficos
Autores principales: Poynard, Thierry, Ratziu, Vlad, Naveau, Sylvie, Thabut, Dominique, Charlotte, Frederic, Messous, Djamila, Capron, Dominique, Abella, Annie, Massard, Julien, Ngo, Yen, Munteanu, Mona, Mercadier, Anne, Manns, Michael, Albrecht, Janice
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1327680/
https://www.ncbi.nlm.nih.gov/pubmed/16375767
http://dx.doi.org/10.1186/1476-5926-4-10
_version_ 1782126514557419520
author Poynard, Thierry
Ratziu, Vlad
Naveau, Sylvie
Thabut, Dominique
Charlotte, Frederic
Messous, Djamila
Capron, Dominique
Abella, Annie
Massard, Julien
Ngo, Yen
Munteanu, Mona
Mercadier, Anne
Manns, Michael
Albrecht, Janice
author_facet Poynard, Thierry
Ratziu, Vlad
Naveau, Sylvie
Thabut, Dominique
Charlotte, Frederic
Messous, Djamila
Capron, Dominique
Abella, Annie
Massard, Julien
Ngo, Yen
Munteanu, Mona
Mercadier, Anne
Manns, Michael
Albrecht, Janice
author_sort Poynard, Thierry
collection PubMed
description BACKGROUND: Biopsy is the usual gold standard for liver steatosis assessment. The aim of this study was to identify a panel of biomarkers (SteatoTest), with sufficient predictive values, for the non-invasive diagnosis of steatosis in patients with or without chronic liver disease. Biomarkers and panels were assessed in a training group of consecutive patients with chronic hepatitis C and B, alcoholic liver disease, and non-alcoholic fatty liver disease, and were validated in two independent groups including a prospective one. Steatosis was blindly assessed by using a previously validated scoring system. RESULTS: 310 patients were included in the training group; 434 in three validation groups; and 140 in a control group. SteatoTest was constructed using a combination of the 6 components of FibroTest-ActiTest plus body mass index, serum cholesterol, triglycerides, and glucose adjusted for age and gender. SteatoTest area under the ROC curves was 0.79 (SE = 0.03) in the training group; 0.80 (0.04) in validation group 1; 0.86 (0.03) in validation group 2; and 0.72 (0.05) in the validation group 3 – all significantly higher than the standard markers: γ-glutamyl-transpeptidase or alanine aminotransferase. The median SteatoTest value was 0.13 in fasting controls; 0.16 in non-fasting controls; 0.31 in patients without steatosis; 0.39 in grade 1 steatosis (0–5%); 0.58 in grade 2 (6–32%); and 0.74 in grade 3–4 (33–100%). For the diagnosis of grade 2–4 steatosis, the sensitivity of SteatoTest at the 0.30 cut-off was 0.91, 0.98, 1.00 and 0.85 and the specificity at the 0.70 cut-off was 0.89, 0.83, 0.92, 1.00, for the training and three validation groups, respectively. CONCLUSION: SteatoTest is a simple and non-invasive quantitative estimate of liver steatosis and may reduce the need for liver biopsy, particularly in patients with metabolic risk factor.
format Text
id pubmed-1327680
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-13276802006-01-14 The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis Poynard, Thierry Ratziu, Vlad Naveau, Sylvie Thabut, Dominique Charlotte, Frederic Messous, Djamila Capron, Dominique Abella, Annie Massard, Julien Ngo, Yen Munteanu, Mona Mercadier, Anne Manns, Michael Albrecht, Janice Comp Hepatol Research BACKGROUND: Biopsy is the usual gold standard for liver steatosis assessment. The aim of this study was to identify a panel of biomarkers (SteatoTest), with sufficient predictive values, for the non-invasive diagnosis of steatosis in patients with or without chronic liver disease. Biomarkers and panels were assessed in a training group of consecutive patients with chronic hepatitis C and B, alcoholic liver disease, and non-alcoholic fatty liver disease, and were validated in two independent groups including a prospective one. Steatosis was blindly assessed by using a previously validated scoring system. RESULTS: 310 patients were included in the training group; 434 in three validation groups; and 140 in a control group. SteatoTest was constructed using a combination of the 6 components of FibroTest-ActiTest plus body mass index, serum cholesterol, triglycerides, and glucose adjusted for age and gender. SteatoTest area under the ROC curves was 0.79 (SE = 0.03) in the training group; 0.80 (0.04) in validation group 1; 0.86 (0.03) in validation group 2; and 0.72 (0.05) in the validation group 3 – all significantly higher than the standard markers: γ-glutamyl-transpeptidase or alanine aminotransferase. The median SteatoTest value was 0.13 in fasting controls; 0.16 in non-fasting controls; 0.31 in patients without steatosis; 0.39 in grade 1 steatosis (0–5%); 0.58 in grade 2 (6–32%); and 0.74 in grade 3–4 (33–100%). For the diagnosis of grade 2–4 steatosis, the sensitivity of SteatoTest at the 0.30 cut-off was 0.91, 0.98, 1.00 and 0.85 and the specificity at the 0.70 cut-off was 0.89, 0.83, 0.92, 1.00, for the training and three validation groups, respectively. CONCLUSION: SteatoTest is a simple and non-invasive quantitative estimate of liver steatosis and may reduce the need for liver biopsy, particularly in patients with metabolic risk factor. BioMed Central 2005-12-23 /pmc/articles/PMC1327680/ /pubmed/16375767 http://dx.doi.org/10.1186/1476-5926-4-10 Text en Copyright © 2005 Poynard et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Poynard, Thierry
Ratziu, Vlad
Naveau, Sylvie
Thabut, Dominique
Charlotte, Frederic
Messous, Djamila
Capron, Dominique
Abella, Annie
Massard, Julien
Ngo, Yen
Munteanu, Mona
Mercadier, Anne
Manns, Michael
Albrecht, Janice
The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis
title The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis
title_full The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis
title_fullStr The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis
title_full_unstemmed The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis
title_short The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis
title_sort diagnostic value of biomarkers (steatotest) for the prediction of liver steatosis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1327680/
https://www.ncbi.nlm.nih.gov/pubmed/16375767
http://dx.doi.org/10.1186/1476-5926-4-10
work_keys_str_mv AT poynardthierry thediagnosticvalueofbiomarkerssteatotestforthepredictionofliversteatosis
AT ratziuvlad thediagnosticvalueofbiomarkerssteatotestforthepredictionofliversteatosis
AT naveausylvie thediagnosticvalueofbiomarkerssteatotestforthepredictionofliversteatosis
AT thabutdominique thediagnosticvalueofbiomarkerssteatotestforthepredictionofliversteatosis
AT charlottefrederic thediagnosticvalueofbiomarkerssteatotestforthepredictionofliversteatosis
AT messousdjamila thediagnosticvalueofbiomarkerssteatotestforthepredictionofliversteatosis
AT caprondominique thediagnosticvalueofbiomarkerssteatotestforthepredictionofliversteatosis
AT abellaannie thediagnosticvalueofbiomarkerssteatotestforthepredictionofliversteatosis
AT massardjulien thediagnosticvalueofbiomarkerssteatotestforthepredictionofliversteatosis
AT ngoyen thediagnosticvalueofbiomarkerssteatotestforthepredictionofliversteatosis
AT munteanumona thediagnosticvalueofbiomarkerssteatotestforthepredictionofliversteatosis
AT mercadieranne thediagnosticvalueofbiomarkerssteatotestforthepredictionofliversteatosis
AT mannsmichael thediagnosticvalueofbiomarkerssteatotestforthepredictionofliversteatosis
AT albrechtjanice thediagnosticvalueofbiomarkerssteatotestforthepredictionofliversteatosis
AT poynardthierry diagnosticvalueofbiomarkerssteatotestforthepredictionofliversteatosis
AT ratziuvlad diagnosticvalueofbiomarkerssteatotestforthepredictionofliversteatosis
AT naveausylvie diagnosticvalueofbiomarkerssteatotestforthepredictionofliversteatosis
AT thabutdominique diagnosticvalueofbiomarkerssteatotestforthepredictionofliversteatosis
AT charlottefrederic diagnosticvalueofbiomarkerssteatotestforthepredictionofliversteatosis
AT messousdjamila diagnosticvalueofbiomarkerssteatotestforthepredictionofliversteatosis
AT caprondominique diagnosticvalueofbiomarkerssteatotestforthepredictionofliversteatosis
AT abellaannie diagnosticvalueofbiomarkerssteatotestforthepredictionofliversteatosis
AT massardjulien diagnosticvalueofbiomarkerssteatotestforthepredictionofliversteatosis
AT ngoyen diagnosticvalueofbiomarkerssteatotestforthepredictionofliversteatosis
AT munteanumona diagnosticvalueofbiomarkerssteatotestforthepredictionofliversteatosis
AT mercadieranne diagnosticvalueofbiomarkerssteatotestforthepredictionofliversteatosis
AT mannsmichael diagnosticvalueofbiomarkerssteatotestforthepredictionofliversteatosis
AT albrechtjanice diagnosticvalueofbiomarkerssteatotestforthepredictionofliversteatosis